
1. malar j. 2020 jun 24;19(1):223. doi: 10.1186/s12936-020-03290-w.

efficacy safety artesunate-amodiaquine artemether-lumefantrine and
prevalence molecular markers associated resistance, guinea: open-label
two-arm randomised controlled trial.

beavogui ah(1)(2)(3), camara a(4)(5)(6), delamou a(7)(4)(5), diallo ms(7),
doumbouya a(7), kourouma k(7), bouedouno p(7), guilavogui t(8), dos santos souza 
s(9), kelley j(10), talundzic e(9), fofana a(11), plucinski mm(12).

author information: 
(1)centre national de formation et de recherche en santé rurale de maferinyah,
forécariah, guinea. bea@maferinyah.org.
(2)department medical sciences, gamal abdel nasser university, conakry,
guinea. bea@maferinyah.org.
(3)centre d'excellence africain pour la prévention et le contrôle des maladies
transmissibles (cea-pcmt), gamal abdel nasser university, conakry, guinea.
bea@maferinyah.org.
(4)centre d'excellence africain pour la prévention et le contrôle des maladies
transmissibles (cea-pcmt), gamal abdel nasser university, conakry, guinea.
(5)department public health, gamal abdel nasser university, conakry, guinea.
(6)national malaria control programme, conakry, guinea.
(7)centre national de formation et de recherche en santé rurale de maferinyah,
forécariah, guinea.
(8)direction epidemiology, ministry health, conakry, guinea.
(9)malaria branch, centers disease control prevention, atlanta, usa.
(10)atlanta research education foundation malaria branch, centers for
disease control prevention, atlanta, usa.
(11)rti international, conakry, guinea.
(12)malaria branch u.s. president's malaria initiative, centers disease
control prevention, atlanta, usa.

background: anti-malarial resistance threat recent gains malaria
control. study aimed assess efficacy safety of
artesunate-amodiaquine (asaq) artemether-lumefantrine (al) management 
of uncomplicated malaria measure prevalence molecular markers of
resistance plasmodium falciparum sentinel sites maferinyah labé
health districts guinea 2016.
methods: two-arm randomised controlled trial efficacy al and
asaq among children aged 6-59 months uncomplicated plasmodium falciparum
malaria two sites. children followed 28 days assess clinical and
parasitological response. primary outcome kaplan-meier estimate of
day 28 (d28) efficacy correction microsatellite-genotyping.
pre-treatment (d0) day failure samples assayed molecular markers 
of resistance pfk13 pfmdr1 genes.
results: total 421 participants included 211 participants the
maferinyah site 210 labé. early treatment failure observed any
study arms. however, 22 (5.3%) participants developed late treatment failure (8
in asaq arm 14 al arm), classified 2
recrudescences 20 reinfections. kaplan-meier estimate corrected
efficacy d28 100% al asaq maferinyah site 99% (95%
confidence interval: 97.2-100%) asaq 99% (97.1-100%) al labé. 
majority successfully analysed d0 (98%, 380/389) day failure (100%,
22/22) samples wild type pfk13. 9 observed pfk13 mutations were
polymorphisms associated artemisinin resistance. nfd haplotype was
the predominant haplotype d0 (197/362, 54%) day failure samples
(11/18, 61%) successfully analysed pfmdr1.
conclusion: study observed high efficacy safety asaq al in
guinea, providing evidence continued use treat uncomplicated
malaria. continued monitoring act efficacy safety molecular makers 
resistance guinea important detect emergence parasite resistance 
to inform evidence-based malaria treatment policies.

doi: 10.1186/s12936-020-03290-w 
pmcid: pmc7315541
pmid: 32580771 

